You are here

Article Text

Article menu
Download PDFPDF
Letter
Time to revisit ‘Megace’ for hot flushes in patients with breast cancer?
  1. Mei-Lin Ah-See
  1. Breast Unit, Mount Vernon Cancer Centre, Northwood, UK
  1. Correspondence to Dr Mei-Lin Ah-See, Breast Unit, Mount Vernon Cancer Centre Ringgold Standard Institution, Rickmansworth Road, Northwood HA6 2RN, UK; m.ah-see{at}nhs.net

https://doi.org/10.1136/bmjspcare-2016-001153

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The NICE guidance on menopause management was eagerly awaited but when it was released in November 20151 it came as a disappointment to many patients with breast cancer struggling with menopausal symptoms, in particular those suffering with hot flushes.

    For this patient group, hormone replacement therapy (HRT) is contraindicated, especially on the back of the HABITS study which demonstrated a threefold increased risk of a new breast cancer event with HRT,2 although interestingly only 21% of patients were on concurrent tamoxifen therapy at the time within this study. The new 2015 NICE guidance refers patients with breast cancer and their clinicians back to …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.